Mirati Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Mirati Therapeutics

28/02/2023 22:05

* Mirati Therapeutics Inc  MRTX.OQ  reported a quarterly
adjusted
loss of $3.51​​ per share for the quarter ended in December. The
mean expectation of seventeen analysts for the quarter was for a
loss of $3.55 per share.
    * Revenue rose 212.4% to $934.00 thousand from a year ago;
analysts expected $2.27 million. 
    * Mirati Therapeutics Inc's reported EPS for the quarter was
a
loss of $3.51​.
    * The mean earnings estimate of analysts had risen by
about 1.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Mirati Therapeutics Inc shares had risen by 2.1% this
quarter.
    * The company reported a quarterly loss of $202.48 million.
    * Wall Street's median 12-month price target for Mirati
Therapeutics Inc is $64.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 10:05 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -3.55          -3.51          Beat
 Sep. 30 2022      -3.48          -3.09          Beat
 Jun. 30 2022      -3.49          -3.18          Beat
 Mar. 31 2022      -3.49          -3.40          Beat